Search company, investor...
Silicon Biosystems company logo

Silicon Biosystems

Founded Year



Acquired | Acquired

About Silicon Biosystems

Silicon Biosystems has developed a set of solutions in the field of lab-on-a-chip technologies targeted at miniaturized single-cell-biology testing, fully exploiting the high potential of microelectronics. The diagnostic approach has led to the possibility of controlling individual cells and micro-particles inside a micro-chamber. Silicon Biosystems technology aims to manage cells on a microelectronic chip, using software control and incorporating sensors to detect the results of complex procedures. Easier recovery of rare fetal cells from maternal blood in prenatal diagnosis can become a routine and non-invasive prenatal procedure, effectively replacing amniocentesis and chorionic villus sampling currently adopted for this purpose. Further applications include the isolation of tumour stem cells, which can be studied in order to define their molecular profiles, detect pre-malignant lesions and target therapies.

Headquarters Location

Via Giuseppe di Vittorio, 21 b/3

Castel Maggiore, 40013,


+39 051 9944100

Missing: Silicon Biosystems's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Silicon Biosystems's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Silicon Biosystems

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Silicon Biosystems is included in 1 Expert Collection, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Silicon Biosystems Patents

Silicon Biosystems has filed 26 patents.

patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Oncology, Transcription factors, Cell biology, Biotechnology


Application Date


Grant Date



Related Topics

Clusters of differentiation, Oncology, Transcription factors, Cell biology, Biotechnology



Latest Silicon Biosystems News

Circulating Tumor Cells (CTC) Global Market Report 2022: Featuring BioFluidica, Fluxion Biosciences, Menarini Silicon Biosystems & More –

Nov 22, 2022

The global circulating tumor cells (CTC) market size reached US$ 9.54 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 18.24 Billion by 2027, exhibiting a CAGR of 11.41% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor. Circulating tumor cells (CTC) are cancer cells that split away from the primary tumor and appear in the circulatory system as singular units or clusters. They have different biological phenotypes, such as epithelial, mesenchymal, and mixed epithelial-mesenchymal. CTC levels in a patient’s blood can allow early detection of cancer and act as a prognostic indicator. As they are in minimal quantity, several technologies are used for the isolation, enrichment, and detection of CTC, such as immunocapture, size-based separation, density-based separation, and microscopy. It also has wide-ranging applications in liquid biopsy, cancer research, drug development, and clinical biomarkers. Circulating Tumor Cells (CTC) Market Trends: increasing prevalence of cancer due to genetic disorders, rising alcohol consumption, and rapid lifestyle changes are key factors driving the market growth. CTC assists in the early identification and real-time monitoring of lung, breast, digestive tract, and prostate cancer. In line with this, the increasing utilization of CTC in patient screening for metastasis and preclinical studies of new cancer drugs is favoring the market growth. Furthermore, the growing demand for minimally invasive (MI) diagnostic procedures and widespread adoption of CTC-based liquid biopsy to enable rapid recovery and limit trauma are providing a considerable boost to the market growth. Apart from this, the introduction of nanotechnology to improve the sensitivity and efficiency of CTC isolation and detection is providing an impetus to market growth. Moreover, increasing utilization in medical research to develop cell culture models for drug screening, disease modeling, genome editing, and tumor immunity is creating a positive outlook for the market. Additionally, the increasing awareness amongst healthcare professionals and patients about the importance of early cancer diagnosis is positively influencing the market growth. Other factors, including rapid advancements in biomedical imaging and bioengineering technology, extensive research and development (R&D) activities, and the rising demand for preventive medicine and companion diagnostics, are anticipated to drive the market growth. Key Market Segmentation: CTC Direct Detection Methods Drug/Therapy Development

Silicon Biosystems Frequently Asked Questions (FAQ)

  • When was Silicon Biosystems founded?

    Silicon Biosystems was founded in 1999.

  • Where is Silicon Biosystems's headquarters?

    Silicon Biosystems's headquarters is located at Via Giuseppe di Vittorio, 21 b/3, Castel Maggiore.

  • What is Silicon Biosystems's latest funding round?

    Silicon Biosystems's latest funding round is Acquired.

  • Who are the investors of Silicon Biosystems?

    Investors of Silicon Biosystems include Menarini Group, JLabs and Innogest Capital.

  • Who are Silicon Biosystems's competitors?

    Competitors of Silicon Biosystems include Endologix, Mercator MedSystems, TruTouch Technologies, Cayenne Medical, SciBase and 12 more.

Compare Silicon Biosystems to Competitors


Renovar, Inc. was founded in 1999 by an internationally-recognized UW-Madison transplant surgeon. The company is developing diagnostic tests for kidney disease and transplant monitoring based on Renovar's patented method. The company's approach couples protein biomarkers and the company's urine buffer system, which permits assaying of urine not possible otherwise. The method aims to enable the potential for non-invasive, timelier disease detection with greater sensitivity and specificity.

ASL Analytical

ASL Analytical is a business-to-business company developing chemical monitors for the bio-manufacturing market. Using measurement technology, ASL is targeting game-changing advances in the development and production of biopharmaceuticals and other biological-based manufacturing markets.


Abla-Tx Inc is a private company founded in 2005 to develop a software based algorithm to monitor thermal ablation of tumors. Abla-Tx has been formed to help guide minimally invasive methods for the treatment of all malignant and benign solid tumors. A patented method of monitoring temperature during thermal ablation in conjunction with CT and digital x-ray imaging will be developed and commercialized. Regulatory approval will be sought to allow the sale of a software based thermal mapping system that will be used in conjunction with CT and planar x-ray imaging systems.

Tears for Life Logo
Tears for Life

Tears For Life, a medical diagnostic equipment company currently developing a non-invasive tear test kit that will be able to screen women for breast cancer using proteins found in their tears.

Rafael Medical Technologies

Rafael Medical has developed a novel anchoring system for safely implanting and retrieving a wide range of intra-vascular devices in a minimally invasive manner. Based on the technology, diagnostic and therapeutic devices can be delivered into small and large blood vessels alike by way of a small-sized delivery system. Following the completion of the SafeFlo Filter the company is now developing additional devices geared to the interventional cardiology market.

Ornim Medical Logo
Ornim Medical

Ornim specializes in clinical research, development, and distribution of the highest quality medical devices in the field of tissue and cerebral blood flow and perfusion. The Company's leading product, the c-FLOW, is a bedside patient monitor based on the patented UTLight technology that provides physicians with unique monitoring solutions, revolutionizing individualized and personalized patient care.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.